Vigilance is Key: Managing ILD with T-DXd

Efficacy in 1st line metastatic breast cancer requires a rigorous safety strategy.

While T-DXd offers transformative results, ILD remains a concern. This clip explores the protocols for proactive monitoring and the clinical reality of managing this risk to ensure long-term patient safety.